Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
Cancer immune therapy for myeloid malignancies: present and future
Morten Orebo Holmström,
Hans Carl Hasselbalch
Department of Clinical Medicine
5
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Cancer immune therapy for myeloid malignancies: present and future'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Cancer Immune Therapy
100%
Immune Response
100%
Chronic Myeloproliferative Neoplasms
100%
Myeloid Malignancies
100%
Treatment Strategy
100%
Immune Regulation
100%
Anticancer Immune Response
100%
Therapeutic Treatment
100%
Calreticulin
50%
Vaccination
50%
Immune Checkpoint Inhibitors
50%
Immune Checkpoint Blocking
50%
Epitope
50%
Exon 9
50%
Tumor Antigen
50%
Driver mutations
50%
Dysregulation
50%
Gene Expression
50%
Arginase-1 (Arg-1)
50%
Immune Parameters
50%
Vaccination Clinic
50%
Clinical Trials
50%
Programmed Death-ligand 1 (PD-L1)
50%
Hematopoietic Stem Cells
50%
Treatment Potential
50%
Immune Cell Function
50%
Cytokine Milieu
50%
Malignancy
50%
Chimeric Antigen Receptor T Cells (CAR-T)
50%
Antitumor Immune Response
50%
Regulatory Proteins
50%
Bone Marrow
50%
Myelodysplastic Syndrome
50%
Immune System
50%
Therapeutic Vaccine
50%
Preclinical Trials
50%
Treatment Options
50%
Acute Myeloid Leukemia
50%
Hypomethylating Agents
50%
Concurrent Use
50%
Lymphoid Malignancies
50%
Deregulation
50%
Checkpoint Blocking Antibody
50%
Medicine and Dentistry
Immunotherapy
100%
Immunity
100%
Myeloid Malignancy
100%
Malignant Neoplasm
100%
Immune Response
60%
Myeloproliferative Neoplasm
40%
Tumor Antigen
20%
Neoplasm
20%
Epitope
20%
Immunoregulation
20%
Lymphoma
20%
Immunocompetent Cell
20%
Immune System
20%
Immune Checkpoint Inhibitor
20%
Blocking Antibody
20%
Diseases
20%
Cell Function
20%
Calreticulin
20%
Cancer
20%
Cytokine
20%
Chimeric Antigen Receptor T-Cell
20%
Myelodysplastic Syndrome
20%
Hematopoietic Cell
20%
Regulator Protein
20%
Arginase 1
20%
Hypomethylating Agent
20%
Acute Myeloid Leukemia
20%
Exon
20%
Programmed Death 1 Ligand 1
20%